Background {#Sec1}
==========

In 2014, UNAIDS proposed the 90-90-90 Fast-Track treatment targets to curb the HIV/AIDS epidemic. These targets stipulate that, by 2020, 90% of people living with HIV worldwide should know their diagnosis, 90% of these people should be on antiretroviral therapy (ART), and 90% of these persons (i.e., 73% of all people living with HIV) should be virally suppressed \[[@CR1]--[@CR3]\]. The HIV care cascade, also known as the HIV care continuum, outlines the sequential steps of HIV care from initial diagnosis to the goal of viral suppression \[[@CR4], [@CR5]\] (Fig. [1](#Fig1){ref-type="fig"}). To achieve universal access to HIV care and treatment with viral suppression, each HIV-positive individual must progress along this cascade. HIV testing services \[[@CR6], [@CR7]\], earlier diagnosis \[[@CR8], [@CR9]\], linkage and retention in care \[[@CR10]--[@CR12]\] and earlier ART initiation \[[@CR13]--[@CR16]\] are key components to achieve the 90-90-90 goals \[[@CR17]\].Fig. 1HIV care cascade and assessment of ART eligibility (adapted from WHO guidelines \[[@CR34]\]). ART, antiretroviral therapy; IDU, injection drug use; LTP, loss to programme; MSM, men who have sex with men; PLHIV, people living with HIV; VL, viral load

The cascade can be used to evaluate HIV programme performance and serve as a monitoring tool to identify gaps and opportunities for specific interventions to improve outcomes \[[@CR18]\]. In sub-Saharan Africa (SSA) and elsewhere, significant gaps remain \[[@CR19]--[@CR21]\], and retention along the HIV care cascade remains a major problem \[[@CR22]--[@CR27]\]. However, studies analysing the HIV care cascade use different methodologies and calculations to construct the cascade. For each element in the cascade, either measured or estimated, definitions vary and methods are often not well described \[[@CR5]\]. The use of different measures, for example how retention in HIV care is defined or the threshold for viral suppression, to estimate the cascade stages may affect the results \[[@CR28]\]. It is therefore difficult to compare published cascades across regions and calendar periods.

Few studies have evaluated the methods used to define the HIV care cascade in low- and middle-income countries, or in SSA \[[@CR18]\]. A previous systematic review from 2014 looking at the whole cascade from HIV testing to viral suppression failed to identify any eligible studies from low-income countries \[[@CR29]\]. A more recent review evaluated the cascade based on national estimates but did not include smaller in-depth studies \[[@CR30]\]. In SSA, surveys conducted between 2007 and 2011 found that 36% of people in the region had never been tested for HIV \[[@CR31]\], and less than 50% of HIV-positive persons knew their HIV status \[[@CR20]\]. Focusing on SSA, we aim to perform a systematic review and meta-regression analysis to assess the different methodological approaches used to define the steps in the HIV care cascade and to estimate the numbers or proportion of people retained in each cascade step.

Methods {#Sec2}
=======

This systematic review protocol was written following the Preferred Reporting Items for Systematic Review and Meta-analysis Protocols (PRISMA-P) guidelines \[[@CR32]\]. The PRISMA-P checklist can be found as Additional file [1](#MOESM1){ref-type="media"}.

Aims {#Sec3}
----

The first aim of this systematic review is to describe the different concepts and methodologies used in the published literature to define the steps in the HIV care cascade in SSA. The second aim is to obtain comparable measures of the number or proportion of people retained in the different steps of the HIV care cascade, based on the findings from the first aim.

Eligibility criteria {#Sec4}
--------------------

### Study designs and setting {#Sec5}

We will include cohort and cross-sectional studies with data collected between January 2004 and March 2016 in any country in SSA (Table [1](#Tab1){ref-type="table"}). Studies that examine two or more of the following cascade elements will be included: the number or proportion of persons diagnosed with HIV (first UNAIDS 90-90-90 treatment target), linkage of HIV-positive persons to pre-ART care, retention in pre-ART care, initiating ART, remaining on ART (second UNAIDS 90-90-90 treatment target), and virological suppression among persons on ART (third UNAIDS 90-90-90 treatment target).Table 1Selection criteriaCriteriaVariablesInclusion criteriaHIV-positive people aged 15 years and older in sub-Saharan AfricaStudy period after 01 January 2004 (ART initiation after 01 January 2004)General populationReporting on a cascade with two or more elements (HIV diagnosed, linked to care, retained in care, on ART, virally suppressed)Observational studies: cohort or cross-sectional studiesPublished in English, French or SpanishExclusion criteria  *Publication type*Narrative reviewsCommentaries, editorials or lettersConference abstracts  *Study design*Randomized controlled trialsQualitative studiesCase seriesSimulations or modelling studiesUnclear study design  *Study population*Populations outside sub-Saharan AfricaChildrenSpecific sub-populations (for example patients with tuberculosis, or pregnant women)

### Population {#Sec6}

We will include studies of the general population living with HIV. This will encompass male and female participants living with HIV-1 aged 15 years or older. We will exclude studies of patients with specific co-morbidities such as tuberculosis or opportunistic infections. Studies in patients with HIV-2 will also be excluded. If the HIV type is not specified, HIV-1 will be assumed. We will exclude studies of prevention of mother-to-child transmission (PMTCT) as the PMTCT care cascade differs substantially from the general HIV care cascade \[[@CR33], [@CR34]\]. We will also exclude intervention studies that examine the effectiveness of measures to improve the HIV care continuum.

### Outcomes {#Sec7}

#### Primary outcomes {#FPar1}

The primary outcome is the concept, methodology and definition used to identify a reported stage of the cascade. We will describe these narratively and classify studies into suitable groups.

#### Secondary outcomes {#FPar2}

The secondary outcomes include the number or proportion of persons retained at each cascade step (see also Fig. [1](#Fig1){ref-type="fig"} and Additional file [2](#MOESM2){ref-type="media"} [)]{.ul}:HIV diagnosis (UNAIDS 90-90-90 treatment target)Linkage to pre-ART careRetention in pre-ART careOn ART (UNAIDS 90-90-90 treatment target) withStart of ARTRetention on ARTSuppression of viral load (UNAIDS 90-90-90 treatment target)

Information sources {#Sec8}
-------------------

### Electronic databases {#Sec9}

We have conducted a comprehensive literature search with the help of two librarians with expertise in systematic reviews. We restricted the search to articles published in English, French and Spanish between January 2004 and March 2016, since the scale-up of ART in SSA started around 2004 \[[@CR35], [@CR36]\]. We performed the searches in PubMed, Embase and CINAHL.

### Search strategy {#Sec10}

The Medical Subject Headings (MeSH terms) for HIV and AIDS and key terms 'cascade', 'continuum', 'linkage to care', 'retention in care' and 'ART initiation' were cross-referenced with terms associated with 62 African countries (Additional file [3](#MOESM3){ref-type="media"} shows the detailed search strategy). We will update the search prior to publication to include any additional eligible papers published after March 2016.

Study records {#Sec11}
-------------

### Data management {#Sec12}

All records from our PubMed, Embase and CINAHL searches will be combined, uploaded into the reference management software Mendeley (version 1.15.3) and de-duplicated. We will use Microsoft Excel (version 2016 for Windows, Microsoft Corp., Redmond, WA, USA) to record outcomes of the selection process.

### Selection of eligible studies {#Sec13}

Two reviewers will independently screen studies in two stages: title/abstract screening, followed by full text screening. A checklist with the eligibility criteria will be developed and pilot-tested on a random sample of 20 studies. Titles and abstracts will then be reviewed against the eligibility criteria by AG and FV. We will obtain full texts of all potentially eligible articles. Two reviewers will independently apply inclusion criteria (Additional file [4](#MOESM4){ref-type="media"}) to the full texts. At both screening steps, we will resolve disagreements by consensus, if necessary through discussion with a third reviewer (CM or ME). We will record all discrepancies on Excel spreadsheets, with reasons for inclusion or exclusion. The PRISMA study flow diagram will reflect this process and detail the reasons for exclusion of studies.

### Data collection {#Sec14}

We will develop a data extraction sheet to guide data collection. This sheet will direct collection of the definition and methods for each step of the cascade, the results of estimations or calculations and sources of data. The sheet will be pilot-tested by two reviewers (AG, CM) on a random sample of 10 articles and revised as needed. Two reviewers will independently read each article and extract the relevant data. Both sets of data will be entered into Epidata version 3.1 (EpiData Association, Denmark). Any discrepancies in the extracted data will be resolved by consensus, in discussion with a third reviewer (CM or ME) if necessary. We will contact study authors to resolve any information that is not clear.

### Data items {#Sec15}

The data items for extraction will be informed by items reported in the PRISMA statement \[[@CR37]--[@CR39]\]. We will extract the following from included studies:Study characteristics (authors, year of publication, study period, study population, study design, aim of study, geographic location, duration of follow-up, key finding);Study setting (location and type of facilities);Characteristics of study populations (sample size, age, sex, marital status, weight, educational level, employment status, enrolment period, inclusion and exclusion criteria);Definitions and methods used to construct cascade;The number or proportion of persons diagnosed with HIV (90-90-90 treatment target), linkage to pre-ART care, retention in pre-ART care, on ART (90-90-90 treatment target), virological suppression (90-90-90 treatment target);Clinical and laboratory data (CD4 cell counts, viral load, ART regimen, medical circumcision (only men), TB status, other co-infections and comorbidities).

### Data synthesis {#Sec16}

The main characteristics of included studies will first be narratively synthesized. Summary statistics will be used to describe study characteristics, including means (standard deviations) or medians (interquartile ranges), and frequencies (percentages). For each step of the cascade, we will calculate proportions with exact binomial 95% confidence intervals (95% CI) and present these in forest plots. We will calculate the between-study variance (tau-squared) and *p* values from tests of between-study heterogeneity. We expect substantial between-study heterogeneity, and the focus of the subsequent analyses will therefore be on the identification and exploration of sources of heterogeneity. We will explore associations between proportions at each step and country, setting (e.g. urban, periurban, rural; health care level, public or private setting) and study characteristics (e.g. study size, sampling frame) using random intercept logistic meta-regression (Binomial-Normal) models. These models avoid the biases that arise when Normal-Normal models (which model the within study variability via normal approximations) are applied to logit or arcsine-square root transformed proportions \[[@CR40], [@CR41]\]. Where appropriate, we will use the same models to calculate combined estimates of proportions. All analyses will be done in R version 3.2.3 (R Foundation, Vienna, Austria).

### Dealing with missing data {#Sec17}

If data are missing in key variables, we will contact the study authors for clarification. A description of missing data will be provided for each study, and we will discuss the possible implications of missing data.

### Risk of bias in included studies {#Sec18}

Two pairs of reviewers (AG and CM) will assess included studies using ROBINS-I, a tool for assessing risk of bias in nonrandomized studies of interventions for observational studies \[[@CR42]\]. The tool will be adapted to the context of this systematic review, and to cross-sectional studies. ROBINS-I contains 34 questions from seven different bias domains. For each study, relevant domains of risk of bias will be graded as low, moderate, serious, critical or no information for risk of bias \[[@CR43]\]. Publication bias will be assessed by visually inspecting funnel plot asymmetry and by including study size in the logistic model. The quality assessment will be cross-checked, and any disagreement will be resolved within the review team.

Discussion {#Sec19}
==========

This systematic review and meta-analysis will contribute to a better understanding of the different methodological approaches used in sub-Saharan African countries to define the steps in the HIV care cascade and to estimate the numbers or percentages of people retained at each step of the cascade. We will identify gaps in the cascade and areas for further research. Our results will be useful for the design of strategies for improving the care and treatment of people living with HIV and for reducing HIV transmission. This review will thus be highly relevant to inform health systems interventions and HIV prevention and treatment strategies in sub-Saharan Africa, and low- and middle-income countries in general.

Additional files
================

 {#Sec20}

Additional file 1:PRISMA-P 2015 Checklist. \[17 items\]. (DOCX 33 kb) Additional file 2:Complete cascade including all steps. A) HIV care cascade as defined by the WHO, B) Assessment of ART eligibility within the HIV care cascade. ART, antiretroviral therapy; D, denominator; LTP\*, loss to programme (pre-ART); LTP\*\*, loss to programme (post-ART); N, nominator; PLD, population level denominator; PBD, programme-based denominator. (JPG 5616 kb) Additional file 3:Search strategy (PubMed, Embase, and CINAHL). (PDF 79 kb) Additional file 4:Study eligibility form. (PDF 114 kb)
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